Here are the 424B prospectus supplements from CalciMedica, Inc. (CALC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. may offer and sell up to $25,000,000 in aggregate gross sales of common stock from time to time through H.C. Wainwright & Co., LLC as sales agent in an at-the-market offering. Sales may be made at prevailing market prices through Nasdaq, other U.S. trading markets, market makers or negotiated transactions. Wainwright is not required to sell a specific amount and will use commercially reasonable efforts; its commission is 3.0% of gross sales price for each sale.
CalciMedica intends to use net proceeds for general corporate purposes, including research and development, clinical trials, capital expenditures and working capital, and may use some for complementary assets or businesses. An illustrative scenario assuming 14,749,262 shares sold at $1.695 per share for $25,000,000 gross proceeds estimates dilution of $0.285 per share. The auditor’s report on the company’s 2025 financial statements includes an explanatory paragraph relating to going-concern uncertainty.